临床阶段生物科技公司 Noxopharm Ltd (ASX股票代码:NOX) 股价连日异动，周二早盘再度飙涨39%，触及0.135澳元高点，近一月涨超140%。

Noxopharm周二披露，自7月16日宣布启动HERACLES 试验以来，首个SOF-SKN剂量队列已成功完成。

安全性指导委员会确定首个剂量水平安全且耐受，第二队列参与者将加入试验，接受更高剂量的测试。

SOF-SKN基于SofraT技术开发，是一种治疗自身免疫性疾病（如皮肤狼疮样红斑）的新型候选药，未来可能用于治疗自身免疫相关的皮肤病，如银屑病和皮肌炎。

Noxopharm首席执行官Gisela Mautner博士表示，能够将首个Sofra候选药快速推向临床阶段，尤其首次将靶向阻断TLR7/8的分子局部应用于人体，令人倍感振奋。

NOX已发行股本2.92亿股，市值近3500万澳元。截止一季度末公司账面现金结余151万澳元。

（图片来源：NOX公告）

（图片来源：NOX官网）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.